GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » EPS (Diluted)

Vifor Pharma AG (LTS:0RPD) EPS (Diluted) : CHF2.22 (TTM As of Dec. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG EPS (Diluted)?

Vifor Pharma AG's Earnings per Share (Diluted) for the six months ended in Dec. 2021 was CHF0.31. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 was CHF2.22.

Vifor Pharma AG's EPS (Basic) for the six months ended in Dec. 2021 was CHF0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2021 was CHF2.23.

Vifor Pharma AG's EPS without NRI for the six months ended in Dec. 2021 was CHF0.34. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2021 was CHF2.25.

During the past 12 months, Vifor Pharma AG's average EPS without NRIGrowth Rate was 1.90% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 1.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 14.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was -9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Vifor Pharma AG's highest 3-Year average EPS without NRI Growth Rate was 66.00% per year. The lowest was -51.10% per year. And the median was 11.50% per year.


Vifor Pharma AG EPS (Diluted) Historical Data

The historical data trend for Vifor Pharma AG's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG EPS (Diluted) Chart

Vifor Pharma AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.67 2.34 2.45 5.53 2.22

Vifor Pharma AG Semi-Annual Data
Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 1.04 4.49 1.91 0.31

Competitive Comparison of Vifor Pharma AG's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vifor Pharma AG's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's PE Ratio distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's PE Ratio falls into.



Vifor Pharma AG EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Vifor Pharma AG's Diluted EPS for the fiscal year that ended in Dec. 2021 is calculated as

Diluted EPS (A: Dec. 2021 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(144.4-0)/65.005
=2.22

Vifor Pharma AG's Diluted EPS for the quarter that ended in Dec. 2021 is calculated as

Diluted EPS (Q: Dec. 2021 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(20-0)/64.921
=0.31

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF2.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vifor Pharma AG  (LTS:0RPD) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Vifor Pharma AG EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Vifor Pharma AG (LTS:0RPD) Business Description

Traded in Other Exchanges
N/A
Address
Rechenstrasse 37, Saint Gallen, CHE, 9014
Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (LTS:0RPD) Headlines

No Headlines